Seer, Inc. Class A (SEER)

In the past six months, Seer, Inc.'s stock has experienced fluctuations influenced by company performance and broader market conditions, closing at $1.95 as of January 9, 2026. In November 2025, the company's shares reacted to its third-quarter 2025 earnings report, which highlighted modest revenue growth, a record number of third-party publications validating its Proteograph platform, and a solid cash position, with total revenue of $4.1 million and a net loss of $18.2 million. In August 2025, Seer, Inc. announced its second-quarter 2025 financial results. In June 2025, an insider sale was reported, with a director selling 30,253 shares. In May 2025, the company reported its first-quarter 2024 financial results, showing a 24% decline in revenue year-over-year, totaling $3.1 million, and outlined strategic measures including a 10% workforce reduction, a $25 million share repurchase program, and expansion of its commercial team.

The provided information does not explicitly indicate any specific demand seasonality for Seer, Inc.'s products and services. The company's revenue is heavily reliant on instrument sales and the adoption of its Proteograph Product Suite. Factors such as macroeconomic headwinds and government funding delays have been noted as potential influences on revenue, but these are not described as seasonal patterns.

Seer, Inc. is a life sciences company focused on developing and commercializing products that decode the biology of the proteome. It operates in the Healthcare sector, specifically in the Biotechnology and Life Sciences Tools and Services industries. Seer's primary product is the Proteograph Product Suite, an integrated solution designed for proteomic analysis, suitable for research use in academic institutions, life sciences and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company's technology aims to provide unbiased, deep, rapid, and large-scale access to the proteome.

Seer, Inc. is headquartered in Redwood City, California, and has a commercial location in San Diego, California. It has an international presence in countries such as China, Australia, Eastern Europe, Israel, Japan, and South Africa. Seer has also launched a European Seer Technology Access Center (STAC).

In the past year, Seer, Inc.'s brand reputation has been shaped by its advancements in proteomics technology and strategic initiatives, with recognition for its focus on decoding the biology of the proteome and its Proteograph Product Suite. The company has been actively involved in advancing proteogenomics research, with recent product-related announcements highlighting its role in this field. The Proteograph XT assay has received positive feedback for enhancing mass spectrometer performance. The company has also emphasized driving evidence and publications to support technology adoption and has launched initiatives like the Seer insights grant program and a European Seer Technology Access Center (STAC) to enhance technology access. The company's financial performance, including revenue decline in Q1 2024 and ongoing net losses, could indirectly influence investor and market perception.

Major institutional owners of Seer, Inc. as of November 2025 include Vanguard Group Inc., Bridgeway Capital Management LLC, and Millennium Management LLC. Other significant institutional holders include Susquehanna International Group LLP, Jacobs Levy Equity Management Inc., Citadel Advisors LLC, Bank of America Corp DE, Shay Capital LLC, Squarepoint Ops LLC, Palumbo Wealth Management LLC, and GSA Capital Partners LLP. The company's CEO, Omid Farokhzad, directly owns 7.39% of the company's shares.